EUVIMEDEUVIMED entdecken
Open Access

CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia

Xi Qin, Keren Zhou, Lei Dong, Lu Yang, Wei Li, Zhenhua Chen, Chao Shen, Li Han, Yangchan Li, Anthony K N Chan, Sheela Pangeni Pokharel, Ying Qing und 8 weitere

Theranostics · 2025

DOI: 10.7150/thno.100295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Xi Qin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Trans-Activators. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTrans-ActivatorsHumansAnimalsMiceCell Line, TumorFusion Proteins, bcr-ablXenograft Model Antitumor AssaysCell Survival

Stichwörter der Autor:innen

B-cell acute lymphoblastic leukemia (B-ALL)CRISPR-Cas9 screenCoRESTFOSZNF217

Substanzen

Fusion Proteins, bcr-ablTrans-Activators

Autor:innen und Institutionen

  • Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
  • Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
  • Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
  • Division of Epigenetic and Transcriptional Engineering, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
  • City of Hope Comprehensive Cancer Center, City of Hope, Duarte, CA 91010, USA.
  • Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Qin, X., Zhou, K., Dong, L., Yang, L., Li, W., Chen, Z., Shen, C., Han, L., Li, Y., Chan, A. K. N., Pokharel, S. P., Qing, Y., Chen, M., Wang, K., Leung, K., Sau, L., Chen, C. W., Deng, X., Su, R., & Chen, J. (2025). CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia. Theranostics. https://doi.org/10.7150/thno.100295

Vancouver

Qin X, Zhou K, Dong L, Yang L, Li W, Chen Z, et al. CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia. Theranostics. 2025. doi:10.7150/thno.100295

BibTeX
@article{Qin2025,
  author = {Qin, Xi and Zhou, Keren and Dong, Lei and Yang, Lu and Li, Wei and Chen, Zhenhua and Shen, Chao and Han, Li and Li, Yangchan and Chan, Anthony K N and Pokharel, Sheela Pangeni and Qing, Ying and Chen, Meiling and Wang, Kitty and Leung, Keith and Sau, Lillian and Chen, Chun-Wei and Deng, Xiaolan and Su, Rui and Chen, Jianjun},
  title = {CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia},
  journal = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.100295}
}
Kostenlos starten →